ScholarIQanswers from OpenAlex & ORCID
Vanna Chiarion‐Sileni
ResearcherPublications, citations & collaboration network
Vanna Chiarion‐Sileni is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Vanna Chiarion‐Sileni have?
ScholarIQindexed works
Vanna Chiarion‐Sileni has 453 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Vanna Chiarion‐Sileni have?
ScholarIQcitation count
Vanna Chiarion‐Sileni has 62,165 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Vanna Chiarion‐Sileni?
ScholarIQh-index
Vanna Chiarion‐Sileni has an h-index of 80 in OpenAlex.
What is the i10-index of Vanna Chiarion‐Sileni?
ScholarIQi10-index
Vanna Chiarion‐Sileni has an i10-index of 220 in OpenAlex.
What is the ORCID of Vanna Chiarion‐Sileni?
ScholarIQorcid
The ORCID for Vanna Chiarion‐Sileni is on the source record.
What is the OpenAlex record for Vanna Chiarion‐Sileni?
ScholarIQopenalex
The OpenAlex for Vanna Chiarion‐Sileni is on the source record.
What are the most-cited papers on Vanna Chiarion‐Sileni?
ScholarIQmost cited works
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial
Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, Helen Gogas, Ana Arance, Stéphane Dalle, C. Lance Cowey, Michael Schenker, Jean-Jacques Grob, Vanna Chiarion‐Sileni, Iván Márquez‐Rodas, Marcus O. Butler, Michele Maio, Mark R. Middleton, Luis de la Cruz‐Merino, Petr Arenberger, Victoria Atkinson, Andrew Hill, Leslie A. Fecher, Michael Millward, Nikhil I. Khushalani, Paola Queirolo, Maurice Lobo, Veerle de Pril, John T. Loffredo, James Larkin, Jeffrey S. Weber
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
Alexander Eggermont, Christian U. Blank, Mario Mandalà, Georgina V Long, Victoria Atkinson, Stéphane Dalle, Andrew Haydon, Andrey Meshcheryakov, Adnan Khattak, Matteo S. Carlino, Shahneen Sandhu, James Larkin, Susana Puig, Paolo A. Ascierto, Piotr Rutkowski, Dirk Schadendorf, Rutger H.T. Koornstra, Leonel F. Hernandez‐Aya, Anna Maria Di Giacomo, Alfons J.M. van den Eertwegh, Jean‐Jacques Grob, Ralf Gutzmer, Rahima Jamal, Paul Lorigan, Alexander C. J. van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marréaud, Michal Kiciński, Stefan Suciu, Caroline Robert, Alex Menzies, Thierry Lesimple, Michele Maio, Gerald P. Linette, Michael P. Brown, Peter Hersey, Inge Marie Svane, Laurent Mortier, Jacob Schachter, Catherine Barrow, Ragini R. Kudchadkar, Xinni Song, Caroline Dutriaux, Pietro Quaglino, Friedegund Meier, Paola Queirolo, Daniil Stroyakovskiy, Lars Bastholt, B. Guillot, Claus Garbe, Pablo L. Ortiz‐Romero, Florent Grange, Peter Mohr, Alain P. Algazi, Oliver Bechter, Micaela Hernberg, Jean‐Philippe Arnault, Philippe Saïag, Carmen Loquai, Frank Meiß, Jan‐Christoph Simon, Gil Bar‐Sela, Vanna Chiarion‐Sileni, Bernard M. Fitzharris, Mike McCrystal, Phillip Parente, Jean‐François Baurain, P. Combemale, Célèste Lebbé, Axel Hauschild, Naoya Yamazaki, Reinhard Dummer, Mohammed Milhem, Marcin Dzienis, John Walker, L. Geoffrois, M.‐T. Leccia, Lutz Kretschmer, Daniel Hendler, Michal Lotem, Andrzej Maćkiewicz, Lidija Kandolf Sekulović, Elaine Dunwoodie, Christoph Höeller, L. Machet, Jessica C. Hassel, Geke A.P. Hospers, Maria-Jose Passos, Max Levin, Martin Fehr, Philippa Corrie, Ashita Waterston, Sigrun Hallmeyer, Henrik Schmidt, V. Descamps, J.‐P. Lacour, Carola Berking, Felix Kiecker, Pier Francesco Ferrucci
Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma
Ermanno Ancona, Alberto Ruol, Stefano Santi, Stefano Merigliano, Vanna Chiarion‐Sileni, H. Koussis, Giovanni Zaninotto, Luigi Bonavina, Alberto Peracchia
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial
Michele Maio, Michele Maio, Karl Lewis, Lev Demidov, Mario Mandalà, Igor Bondarenko, Paolo A Ascierto, Christopher Herbert, Andrzej Maćkiewicz, Piotr Rutkowski, Alexander Guminski, Grant R. Goodman, Brian Simmons, Chenglin Ye, Yibing Yan, Dirk Schadendorf, Gabriela Cinat, Luis Fein, Michael P. Brown, Alexander Guminski, Andrew Haydon, Adnan Khattak, Catriona M. McNeil, Phillip Parente, Jeremy Power, Rachel Roberts‐Thomson, Shahneen Sandhu, Craig Underhill, Suresh Varma, Thomas Berger, Ahmad Awada, Nathalie Blockx, Véronique Buyse, Jeroen Mebis, Fábio Franke, Sérgio Jobim Azevedo, Nicolas Lazaretti, Rahima Jamal, Catalin Mihalcioiu, Teresa M. Petrella, Kerry J. Savage, Ralph Wong, Ralph Wong, Nina Dabelić, Stjepko Pleština, Željko Vojnović, Petr Arenberger, Ivo Kocák, Ivana Krajsová, Eugen Kubala, Bohuslav Melichar, Yvetta Vantuchová, Kadri Putnik, Brigitte Dréno, Caroline Dutriaux, Jean‐Jacques Grob, P. Joly, J.‐P. Lacour, Nicolás Meyer, Laurent Mortier, L. Thomas, Michael Fluck, Thilo Gambichler, Jessica C. Hassel, Axel Hauschild, Dirk Schadendorf, Paul Donnellan, John McCaffrey, Derek G. Power, Samuel Ariad, Gil Bar‐Sela, Daniel Hendler, Ilan G. Ron, Jacob Schachter, Paolo Ascierto, Alfredo Berruti, Luca Bianchi, Vanna Chiarion‐Sileni, Francesco Cognetti, Riccardo Danielli, Anna Maria Di Giacomo, Luca Gianni, Aron Goldhirsch, Michele Guida, Michele Maio, Michele Maio, Mario Mandalà, Paolo Marchetti, Paola Queirolo, Armando Santoro, Ellen Kapiteijn, Andrzej Mackiewicz, Piotr Rutkowski, P. Ferreira, Lev Demidov, Georgy Gafton, Yulia Makarova, Zoran Andrić, Nada Babović, Darjana Jovanovic